CDMRP Neurofibromatosis Investigator-Initiated Research Program
ID: 355151Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355151
Timeline
    Description

    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the Neurofibromatosis Investigator-Initiated Research Program grant to support innovative research projects aimed at advancing the understanding and treatment of neurofibromatosis (NF). This funding opportunity encourages high-impact research proposals that address clinical challenges associated with NF1, NF2, and schwannomatosis, with a total estimated program funding of approximately $5.36 million for FY24 and an expected six awards. Interested applicants, particularly those with a Principal Investigator at least at the Assistant Professor level, must submit pre-applications by September 12, 2024, and full applications by October 3, 2024, with peer reviews scheduled for December 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524NFRPIIRA_GG.pdf
    The DOD FY24 Neurofibromatosis Investigator-Initiated Research Award is a funding opportunity from the Department of Defense aimed at advancing research on neurofibromatosis (NF) to improve outcomes for affected individuals, including military personnel. The program seeks innovative and high-impact research proposals that address the clinical challenges of NF1, NF2, and schwannomatosis. The total funding for FY24 is approximately $25 million, with a maximum direct cost limit of $575,000 for Level 2 applications including a Qualified Collaborator or NF Open Science Initiative option. Pre-applications must be submitted by September 12, 2024, and full applications by October 3, 2024, with peer review occurring in December 2024. Applicants can be from diverse organizations, provided they meet eligibility criteria, particularly having a Principal Investigator at least at the Assistant Professor level. The review process consists of a peer evaluation focusing on the research strategy, impact, personnel qualifications, and budget, followed by a programmatic review to determine funding relevance. The initiative encourages collaboration, data sharing, and addressing critical needs within the NF community. The ultimate aim is to foster translational research that directly benefits Service Members, Veterans, and the general public by enhancing the understanding and treatment of neurofibromatosis.
    Similar Opportunities
    CDMRP Neurofibromatosis New Investigator Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis New Investigator Award to support innovative research in neurofibromatosis (NF). This grant aims to foster the development of early-stage investigators and facilitate the transition of established researchers from other fields into NF research, with a focus on enhancing understanding, diagnosis, and treatment of NF. Eligible applicants include both early-stage and established investigators, and while prior experience in NF research is not required, collaboration with experienced researchers is encouraged. The total estimated funding for this program is $2,880,000, with up to four awards expected, each allowing for direct costs not exceeding $450,000 over a maximum of three years. Interested applicants must submit a pre-application by October 3, 2024, followed by a full application, and can reach the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the Neurofibromatosis Early Investigator Research Award, a federal grant aimed at supporting innovative research in neurofibromatosis (NF). This opportunity is specifically designed for early-stage investigators to develop research projects under the guidance of experienced mentors, focusing on understanding, diagnosing, and treating NF1, NF2, and schwannomatosis disorders. With a total estimated program funding of $640,000 and an expected two awards, each grant will not exceed $200,000 over a performance period of two years. Interested applicants must submit their proposals by October 3, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Synergistic Idea Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research Acquisition Activity, is offering the Neurofibromatosis Synergistic Idea Award, a federal grant aimed at fostering collaborative research projects focused on neurofibromatosis (NF). This award encourages innovative, multidisciplinary approaches involving two or three Principal Investigators (PIs) to address significant challenges in NF research, with an emphasis on developing new therapeutics and enhancing research capacity. With an estimated total program funding of $6.4 million for FY24 and the expectation of awarding two grants, interested applicants must submit a pre-application letter of intent by September 12, 2024, followed by full applications due by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    CDMRP Neurofibromatosis Exploration-Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis Exploration-Hypothesis Development Award, aimed at funding innovative research related to neurofibromatosis (NF). This grant supports the exploration of high-risk, high-gain concepts to enhance understanding and treatment of NF1, NF2, and schwannomatosis, with an estimated total program funding of $1.12 million and the expectation to fund approximately seven projects. The application process is two-tiered, requiring pre-applications by September 12, 2024, and full applications by October 3, 2024, with a focus on innovation, research feasibility, and impact on NF research and patient care. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 Neurofibromatosis Clinical Trial Award to support innovative clinical trials aimed at addressing high-impact issues related to neurofibromatosis (NF), including NF1, NF2, and schwannomatosis. Applicants are required to present a clear clinical trial design, preliminary data, and access to suitable patient populations, with a focus on enhancing understanding, diagnosis, and treatment of NF to benefit service members, veterans, and the public. This funding opportunity, totaling approximately $1.6 million for the award, encourages collaborative proposals involving academia, industry, and military branches, with key deadlines for pre-applications on September 12, 2024, and full applications by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    NFRP Outreach and Invitation for Response
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    DoD Multiple Sclerosis, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Multiple Sclerosis Research Program (MSRP) via the Investigator-Initiated Research Award (IIRA). This grant aims to support innovative and high-impact research projects related to Multiple Sclerosis (MS), particularly those that can enhance patient care and quality of life, while excluding clinical trials. The program emphasizes research on central nervous system repair, disease progression correlates, symptom biology, and MS etiology, with a total funding pool of $6 million expected to yield approximately six awards, each up to $1 million over three years. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Bone Marrow Failure, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Bone Marrow Failure Research Program (BMFRP) Investigator-Initiated Research Award, aimed at advancing research on bone marrow failure (BMF) diseases. This grant opportunity includes two funding levels: Funding Level 1 (FL1) focuses on developing mature ideas and translating discoveries into clinical applications, while Funding Level 2 (FL2) supports efforts to facilitate Investigational New Drug (IND) applications for promising therapeutic candidates. With a total estimated funding of $2.44 million available for two awards, the program encourages innovative and collaborative research proposals that address critical questions in BMF disease management. Interested applicants must submit a pre-application by July 17, 2024, with the full application due by October 9, 2024; for assistance, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Multiple Sclerosis, Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Early Investigator Research Award (MSRP EIRA) to support innovative research focused on multiple sclerosis (MS) by early-stage investigators. This grant aims to foster the development of postdoctoral researchers with less than four years of experience, encouraging them to collaborate with experienced mentors to address critical needs in MS research, particularly in areas such as CNS repair, disease activity correlates, and MS symptomatology. The total funding available for this program is $1.6 million, with an expected five awards, each providing a maximum budget of $320,000 over two years. Key deadlines include a pre-application due by July 24, 2024, and a full application due by October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Bone Marrow Failure, Idea Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Bone Marrow Failure Research Program (BMFRP) Idea Development Award for FY24, aimed at supporting innovative research to understand and cure bone marrow failure diseases. This grant opportunity encourages both Established Investigators and Early-Career Investigators to propose high-impact research studies with a strong scientific rationale, focusing on conditions such as Aplastic Anemia and Fanconi Anemia, while excluding funding for clinical trial costs. With an estimated total program funding of $4.24 million and the expectation of awarding five grants, interested applicants must submit a pre-application through eBRAP followed by a full application via Grants.gov by the deadline of October 9, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.